EBS Emergent BioSolutions Inc

  1. Stocks
  2. Healthcare
  3. NYSE: EBS

Price (delayed)

$8.28

Market cap

$427.22M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.14

Enterprise value

$839.32M

?
Relative Growth: Rel. Growth: 26
Relative Strength: Rel. Strength: 29
Relative Valuation: Rel. Valuation: 62
Relative Profitability: Rel. Profitability: 61

Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through their specialty products and contract development and manufacturing services, the company is dedicated ...

Highlights
Emergent BioSolutions's debt has decreased by 14% YoY
The net income has plunged by 116% from the previous quarter but it has soared by 93% YoY
EBS's EPS has dropped by 114% since the previous quarter but it has soared by 94% year-on-year
EBS's quick ratio is down by 40% YoY and by 14% QoQ
The company's revenue fell by 30% YoY and by 9% QoQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.emergentbiosolutions.com
Peers: MRK SIGA XOMA CLDX

Key stats

What are the main financial stats of EBS

EBS stock price

How has the Emergent BioSolutions stock price performed over time
Intraday
0%
1 week
3.76%
1 month
0.85%
1 year
16.46%
YTD
-33.01%
QTD
-1.19%

Financial performance

How have Emergent BioSolutions's revenue and profit performed over time
Revenue
$676.8M
Gross profit
$367.1M
Operating income
$60.7M
Net income
-$8.6M
Gross margin
54.2%
Net margin
-1.3%
The company's operating margin has surged by 188% YoY but it fell by 33% QoQ
EBS's operating income has soared by 162% YoY but it is down by 39% from the previous quarter
Emergent BioSolutions's net margin has shrunk by 118% QoQ but it has surged by 90% YoY
The net income has plunged by 116% from the previous quarter but it has soared by 93% YoY

Price vs fundamentals

How does EBS's price correlate with its fundamentals

Growth

What is Emergent BioSolutions's growth rate over time

Valuation

What is Emergent BioSolutions stock price valuation
EBS P/E details
P/E
N/A
P/B
0.82
P/S
0.63
EV/EBIT
14.2
EV/EBITDA
5.49
EV/Sales
1.24
EBS's EPS has dropped by 114% since the previous quarter but it has soared by 94% year-on-year
The price to book (P/B) is 9% lower than the last 4 quarters average of 0.9 but 2.5% higher than the 5-year quarterly average of 0.8
EBS's equity is down by 5% year-on-year
The company's revenue fell by 30% YoY and by 9% QoQ
The P/S is 5% above the 5-year quarterly average of 0.6 and 5% above the last 4 quarters average of 0.6

Efficiency

How efficient is Emergent BioSolutions business performance
EBS's return on equity has dropped by 117% since the previous quarter but it has surged by 94% year-on-year
The company's return on assets has shrunk by 116% QoQ but it has surged by 93% YoY
EBS's ROIC has shrunk by 57% QoQ
EBS's ROS has dropped by 54% since the previous quarter

Dividends

What is EBS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EBS.

Financial health

How did Emergent BioSolutions financials performed over time
The total assets is 66% more than the total liabilities
EBS's quick ratio is down by 40% YoY and by 14% QoQ
Emergent BioSolutions's current ratio has decreased by 32% YoY and by 14% from the previous quarter
Emergent BioSolutions's debt is 10% higher than its equity
Emergent BioSolutions's debt has decreased by 14% YoY
The debt to equity has decreased by 8% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.